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Context: It has been hypothesized that depression is as-
sociatedwith lowerheart ratevariabilityanddecreasedcar-
diac vagal control. This may play an important role in the
riskofcardiovasculardiseaseamongdepressed individuals.
Objective: To determine whether heart rate variability
was lower in depressed individuals than in healthy con-
trols in a large adult sample.
Design: Cross-sectional analyses from a large depres-
sion cohort study.
Setting: The Netherlands Study of Depression and
Anxiety.
Participants: Two thousand three hundred seventy-
three individuals (mean age, 41.8 years; 66.8% female)
who participated in the Netherlands Study of Depres-
sion and Anxiety. Included were 524 controls, 774 in-
dividuals with a diagnosis of major depressive disorder
(MDD) earlier in life (remitted MDD), and 1075 indi-
viduals with current MDD based on the Composite In-
ternational Diagnostic Interview. This sample was suf-
ficiently powered to examine the confounding effects of
lifestyle, comorbid anxiety, and antidepressants.
Main Outcome Measures: The standard deviation of
normal-to-normal beats (SDNN) and cardiac vagal con-
trol, as indexedby respiratory sinus arrhythmia (RSA),were
measuredduring11⁄2 hoursof ambulatory recordingof elec-
trocardiograms and thorax impedance.Multivariate analy-
ses were conducted to compare SDNNandRSA across de-
pression groups after adjustment for demographics, health,
lifestyle, comorbid anxiety, and psychoactive medication.
Results: Individuals with remitted and currentMDDhad
a lower mean SDNN and RSA compared with controls
(SDNN, 3.1-5.7 milliseconds shorter, P .02; RSA, 5.1-
7.1 milliseconds shorter, P .001; effect size, 0.125-
0.269).Comorbid anxiety and lifestyle didnot reduce these
associations. However, accounting for psychoactivemedi-
cation removed the association with SDNN and strongly
attenuated the association with RSA. Depressed individu-
als who were using selective serotonin reuptake inhibi-
tors, tricyclic antidepressants, or other antidepressants had
significantly shorter SDNNs and RSAs (effect size, 0.207-
0.862) comparedwith controls and depressed individuals
not taking medication.
Conclusions: This study shows that depression is asso-
ciated with significantly lowered heart rate variability.
However, this association appears to be mainly driven
by the effect of antidepressants.
Arch Gen Psychiatry. 2008;65(12):1358-1367
D EPRESSION RESULTS IN UN-favorable health out-comes, such as cardiovas-cular morbidity andmortality.1-6 Alterations in
the autonomic nervous system have been
hypothesized to be an underlying physi-
ological mechanism that may partly ex-
plain these unfavorable health outcomes
among depressed persons.7-11 Such alter-
ations are believed to reduceheart rate vari-
ability, awell-knownprognostic risk factor
for cardiovascular disease (eg, myocar-
dial infarct and arrhythmias), and mor-
tality.12-18 In research on autonomic ner-
vous system correlates of depression,most
attention has been focused on low car-
diac vagal control, which may impair so-
cial engagement and flexible adjustment
to environmental demands19-22 andmay be
amajor determinant of a reduction in heart
rate variability.
Cardiac vagal control can be assessed by
examining heart rate variability, particu-
larly that in the respiratory frequency range.
This part of heart rate variability is also
known as respiratory sinus arrhythmia
(RSA).23 In a recentmeta-analysis, Rotten-
berg22 examined theassociationbetweende-
pression and RSA. Themeta-analysis sum-
marized 13 studies that reported on RSA
measures,with a total of 312depressed sub-
Author Affiliations are listed at
the end of this article.
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jects and 374 controls. Depressed persons were found to
have a significantly shorter RSA, though the summarized
effect size was small to medium according to Cohen con-
ventions (d=0.332). As pointed out by Rottenberg, data
collection and analysis differed considerably among the
studies and only a few of them had the required sample
size to address confounding by lifestyle (smoking, use of
alcohol, high bodymass index, and low physical activity)
and comorbid anxiety. However, many of these factors—
substance use, low physical activity, and comorbid anxi-
ety—occur frequently in depression and have been asso-
ciated with decreased cardiac vagal control.24,25 Finally,
antidepressants are a particularly relevant source of po-
tential confounding when examining the association be-
tween depression and cardiac vagal control. The suppres-
sive effects of tricyclic antidepressants (TCAs) on
autonomic function are already well established.26-31 The
effect of other antidepressants onautonomic function,how-
ever, are not as well studied and inconsistent results have
been reported.29,32-34 The present study reports cross-
sectional analyses from a large depression cohort study
(Netherlands Study of Depression andAnxiety [NESDA],
N=2981).We examinedwhether heart rate variability, as
indexed by the standard deviation of normal-to-normal
beats (SDNN), and cardiac vagal control, as indexed by
RSA derived from peak-valley estimation,35,36 differed be-
tween depressed individuals and healthy controls. The
study was sufficiently powered to examine the extent to
which these associations are confounded by lifestyle, co-
morbid anxiety, and effect of antidepressants.
METHODS
PARTICIPANTS
Study participants came from NESDA, an ongoing 8-year lon-
gitudinal cohort study conducted among 2981 adults (age, 18-65
years). The study examines the etiology and predictors of a long-
term course of depression and anxiety disorders. Its ration-
ales, methods, and recruitment strategy have been described
elsewhere.37 The NESDA sample consists of 652 persons with-
out depression or an anxiety disorder and 2329 with a remit-
ted or current diagnosis of depression or an anxiety disorder.
To represent various settings and stages of psychopathology,
individuals with depression or anxiety disorders were re-
cruited from 3 different areas in the Netherlands: the general
population, primary care, and mental health care organiza-
tions. Community-based participants were previously identi-
fied in 2 population-based studies (the NEMESIS and Ariadne
studies37); primary care participants were identified through a
3-stage screening procedure (involving the Kessler Psychologi-
cal Distress Scale [K10]38,39 and the short form of the Compos-
ite International Diagnostic Interview [CIDI], telephone inter-
view) conducted among patients of 65 general practitioners;
andmental health care patients were recruited when they were
newly enrolled at 1 of 17 participating mental health organi-
zation locations.
Participants in NESDAwere assessed during a 4-hour clinic
visit to 1 of 7 field center locations (September 2004-February
2007). During this visit, depressive disorders were ascer-
tained using the lifetime version of the CIDI. The CIDI estab-
lishes diagnoses according toDSM-IV criteria40 and has shown
high interrater and test-retest reliability and validity for de-
pressive disorders.41 The severity of depression was measured
in all participants using the 30-item Inventory of Depressive
Symptomatology, Self-Report (IDS-SR).42
To test whether SDNN and RSA differed across persons with
andwithout a depressive disorder, 3 distinct depression groups
were created for the present study: 524 controls with no his-
tory of depression or anxiety disorders and low scores on a de-
pressive symptom questionnaire (IDS-SR score14); 774 per-
sons with a major depressive disorder (MDD) diagnosis
(according to CIDI) earlier in life but not within the past 6
months (remittedMDD group); and 1075 persons with a CIDI-
confirmedMDD diagnosis within the past 6 months (72% had
experienced a depressive episode in the past month) (current
MDD group). The remaining 608 individuals were excluded
from the analyses: 128 controls had an IDS-SR score greater
than 14; 404 patients had an anxiety disorder, minor depres-
sion, or dysthymia in absence of anMDDdiagnosis; and 76 had
missing physiological data owing to equipment failure during
assessment or poor electrocardiogram quality.
MEASUREMENTS
The baseline assessment consisted of a blood sample, cognitive
computer task, medical examination, psychiatric interview, sa-
liva collection, and administration of several written question-
naires concerning, eg,mood, lifestyle,medical history, andmedi-
cationuse. In thisway, extensive informationaboutpsychological,
biological, physical, and demographic determinants were col-
lected. The study protocol was approved by the ethics review
board of the VUUniversityMedical Center and subsequently by
local review boards of each participating center. All participants
signed an informed consent at baseline.
PHYSIOLOGICAL MEASUREMENTS
Physiological recording was performed using the Vrije Univer-
siteit Ambulatory Monitoring System (VU-AMS; Vrije Univer-
siteit, Amsterdam, the Netherlands). The VU-AMS is a light-
weight portable device that records electrocardiograms and
changes in thorax impedance from 6 electrodes placed on the
chests and backs of participants.43,44 Recording is unobtrusive,
and participants, whomaintain full freedom ofmovement, tend
to adjust very rapidly to this type of recording. TheNESDA par-
ticipants wore the VU-AMS device during a large part of the
baseline assessments while participating in other assessments
(medical examination, interviewing, and computer task). The
start of the various assessmentswas indicated by an eventmarker
to divide the total recording into fixed periods (resting base-
line, breaks, interview 1, computer task, and interview 2).Move-
ment registration by a vertical accelerometer was used to ex-
cise periods in which participants were not stationary. Removal
of breaks and nonstationary moments (about 15 minutes) left
an average registration of 99.9minutes (standard deviation [SD],
23.0 minutes). This registration consisted of a supine resting
condition (with 3 blood pressure measurements; mean time,
9.7 minutes [SD, 3.0 minutes]) and 3 test conditions in which
the participants were sitting upright: interview session 1 (in-
vestigating somatic health, functioning, and health care use;
mean, 38.2 minutes [SD, 12.7 minutes]), interview session 2
(investigating family and personal history and life events; mean,
35.6 minutes [SD, 12.7 minutes]), and a computer task (Im-
plicit Association Task; mean, 16.2 minutes [SD, 4.0 min-
utes]). The Implicit Association Task is a computerized reac-
tion time task designed tomeasure implicit associations between
self-describing items and anxiety- anddepression-related items.45
From the electrocardiogram and the thorax impedance data,
interbeat interval time series and respiration signal were ex-
tracted as described elsewhere.43,46,47 From these signals, themean
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heart rate, SDNN, and RSA were computed for each of the 4
conditions (rest, interview 1, computer task, and interview 2).
Heart rate and SDNN were directly derived from the interbeat
interval time series as was a first RSA measure, the root mean
square of successive differences (RMSSD). A second RSAmea-
sure was obtained by directly combining the electrocardio-
gram data with the respiration signal to obtain the variation in
the interbeat intervals restricted to the typical respiratory fre-
quency range (0.15-0.40 Hz). Extraction of RSA by this peak-
valley estimation (pvRSA) has been detailed elsewhere.36,48 A
third, more labor-intensive measure of RSA could have been
obtained in the frequency domain, like the high-frequency power
of the interbeat interval time series by Fourier orWavelet analy-
sis.49 It has been shown, however, that high-frequency power
essentially identifies the same between-subject variation as
RMSSD and pvRSA and that all 3 measures can be used inter-
changeably.36,46 Because results fromRMSSDandpvRSA strongly
converged in the current data, we have focused on pvRSA. This
measure has the added advantage over the frequency domain
method of yielding information on the respiratory frequency
of participants. This is important because the widespread use
of RSA as a proxy for individual differences in cardiac vagal con-
trol23,50 suffers from potential confounding by individual dif-
ferences in respiratory behavior.51,52
COVARIATES
Respiration rate has often been associated with RSA and several
studies have asserted that research investigating RSA should take
respiration rate into account.43,53 Therefore, we adjusted analy-
ses for respiration rate. Sociodemographic characteristics in-
cluded age, sex, and education in years. In addition, varioushealth
indicators were considered covariates, as these have been linked
with both depression status and cardiac vagal control. Bodymass
indexwas calculated as weight in kilograms divided by height in
meters squared and categorized following World Health Orga-
Table 1. Sample Characteristics by MDD Diagnosis
Characteristic
Participants, %
P Valuea
Control
(n=524)
With Remitted MDD
(n=774)
With Current MDD
(n=1075)
Age, mean (SD), y 40.7 (14.8) 43.5 (12.6) 40.8 (12.1) .001
Female sex 59.7 70.5 67.4 .001
Education, mean (SD), y 13.0 (3.1) 12.4 (3.2) 11.6 (3.2) .001
Body mass indexb
Mean (SD) 25.1 (4.6) 25.6 (4.7) 25.9 (5.5) .01
Underweight 3.2 2.3 4.1
.004Normal weight 53.1 49.1 47.5
Overweight 29.6 32.8 28.1
Obese 14.1 15.8 20.3
Physical activity, resting metabolic rate  min
of physical activity per week
Mean (SD) 3.9 (3.0) 3.9 (3.1) 3.6 (3.3) .14
Low 12.8 15.2 21.1
.001Moderate 37.2 37.3 36.3
High 50.0 47.5 42.6
Smoking status
Nonsmoker 37.4 23.5 26.4
.001Former smoker 36.1 37.0 28.4
Moderate smoker 21.9 29.3 27.8
Heavy smoker 4.6 10.2 17.4
Alcohol use
Nondrinker 10.5 15.2 21.7
.001Mild drinker 48.5 44.2 45.6
Moderate drinker 23.9 24.7 17.6
Heavy drinker 17.2 15.9 15.2
Heart or blood pressure medication 13.9 15.5 13.0 .32
Heart or coronary disease 4.0 7.1 5.4 .05
Chronic diseases, mean (SD), No. 0.95 (1.0) 1.28 (1.3) 1.46 (1.3) .001
Medication use
Tricyclic antidepressant 0.2 2.8 4.2 .001
Selective serotonin reuptake inhibitor 0.6 16.3 29.2 .001
Other antidepressant 0.0 3.9 11.2 .001
Benzodiazepine 1.0 4.7 15.0 .001
Other psychotropic medication 5.5 6.3 5.1 .53
Comorbid anxiety
Panic disorder 0 41.3 52.0 .001
Social phobia 0 32.3 41.7 .001
Generalized anxiety disorder 0 28.8 39.0 .001
Respiration rate, mean (SD), breaths/min 17.2 (1.2) 17.0 (1.2) 17.1 (1.2) .07
IDS-SR score, mean (SD) 5.6 (3.9) 17.6 (10.3) 31.9 (13.0) .001
Abbreviations: IDS-SR, Inventory of Depressive Symptomatology, Self-Report; MDD, major depressive disorder.
aComparison using analyses of variance (continuous variables) and 2 statistics (categorical variable).
bCalculated as weight in kilograms divided by height in meters squared.
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nization international standards54: underweight (18.5), nor-
mal weight (18.5 and25), overweight (25 and30), and
obese (30). Physical activity was measured using the Interna-
tional Physical Activity Questionnaire55 and expressed as one’s
resting metabolic rate multiplied by minutes of physical activity
per week. Individuals were divided into the following smoking
categories: nonsmoker, former smoker, smoker (20 tobaccocon-
sumptions a day), and heavy smoker (20 tobacco consump-
tions a day). Similar categories were made for alcohol use: non-
drinker,milddrinker (7glasses aweek),moderatedrinker (7-14
glasses a week), and heavy drinker (15 glasses a week). Self-
reports were used to ascertain the presence of heart disease (in-
cludingcoronarydisease, cardiacarrhythmia, anginapectoris,heart
failure, andmyocardial infarction)and thenumberofother chronic
conditions (epilepsy, diabetes, osteoarthritis, stroke, cancer,
chronic lung disease, thyroid disease, liver disease, chronic fa-
tigue syndrome, intestinal disorders, and ulcers [stomach or in-
testinal]). Itwasdeterminedwhetherornotparticipantswereusing
heartmedication by recordingmedication names from themedi-
cine bottles they brought in. We classified medications by using
theWorldHealthOrganizationAnatomical Therapeutic Chemi-
cal (ATC) system.56 A dichotomous variable for heart medica-
tion was computed, giving participants a yes if they frequently
(daily or50% of the time) used a medication, with the follow-
ingATCcodes: cardiac therapy,C01; antihypertensivedrugs,C02;
diuretic drugs, C03; peripheral vasodilator drugs, C04; vasopro-
tective drugs, C05; -blocking agents, C07; and calcium-
channel blockers, C08.
Subsequently, potentially explanatory variables were deter-
mined. The presence or absence of a comorbid lifetime panic
disorder (with or without agoraphobia), comorbid lifetime so-
cial phobia, or comorbid lifetime generalized anxiety disorder
was assessed using CIDI. In addition, frequent use (daily or
50% of the time) of psychoactive medication was deter-
mined. We distinguished benzodiazepine drugs (ATC codes
N03AE, N05BA, N05CD, and N05CF), selective serotonin re-
uptake inhibitors (SSRIs) (ATC codeN06AB), TCAs (ATC code
N06AA), and other antidepressants (includingmonoamine oxi-
dase inhibitors, nonselective N06AF, and antidepressants clas-
sified asN06AX) fromnondepression-relatedpsychoactivemedi-
cation (anesthetic drugs, ATC code N01; analgesic drugs, ATC
code N02; antiepileptic drugs, ATC code N03; anti-Parkinson
disease drugs, ATC code N04; psycholeptic drugs, ATC code
N05; psychostimulants, ATC code N06B; antidementia drugs,
ATC code N06D; and other nervous system drugs, ATC code
N07). For all psychoactivemedication, a derived daily dose was
calculated by dividing the participant’s mean daily dose by the
daily dose recommended by theWorld Health Organization.56
STATISTICAL ANALYSIS
Data were analyzed using SPSS, version 15.0 (SPSS Inc, Chi-
cago, Illinois).Characteristics across the3depressiongroupswere
comparedusing analysis of variance and2 statistics.Mixedmodel
analysis was used to compare heart rate, SDNN, and RSA be-
tween the control, remittedMDD, andcurrentMDDgroups across
the 4 different interview conditions to establish whether the as-
sociation between MDD group and cardiac measure was con-
stant across assessment conditions. Analyses of covariancewere
used to compare heart rate, SDNN, and RSA between MDD
groups. These analyses were repeated with consideration of co-
variates (respiration rate, age, sex, education, body mass index,
smoking, alcohol use, physical activity, heart disease, heartmedi-
cation, and number of comorbid diseases). Effect sizes were cal-
culated with Cohen d, defined as the difference in the means of
2groups, dividedby thepooled standarddeviationof thesegroups.
Subsequently, the role of 2 main explanatory variables (comor-
bid anxiety and psychoactive medication) was examined by en-
tering information on these variables in the analyses of covari-
ance. We distinguished between MDD participants taking and
not taking various types of psychoactive medication and com-
pared their cardiac measures with those of controls in fully cor-
rected analyses of covariance. Finally, to explore a potential dose-
response association, a sex- and age-adjusted partial correlation
between the derived daily dose and cardiac measures was com-
puted for each antidepressant group.
RESULTS
The mean age of the study sample (N=2373) was 41.6
years (SD, 13.0 years); 66.8% of participants were fe-
male; and 50.2% had less than 12 years of education.
Table 1 presents demographic characteristics, disease
status, lifestyle habits, and medication use according to
MDD status. Compared with the nondepressed partici-
pants, depressed individuals were more likely to be fe-
male, had less education, had higher body mass in-
dexes, performed less physical activity, were more likely
to smoke but less likely to drink, had more heart disease
and other chronic diseases, were more likely to use an-
tidepressants, and had higher IDS-SR scores.
Figure 1 shows heart rate, SDNN, and RSA results
per assessment condition for the 3 depression groups. It
illustrates that heart rate is approximately the same in
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Figure 1. Autonomic nervous system activity during assessment conditions
across depression groups. MDD indicates major depressive disorder;
RSA, respiratory sinus arrhythmia; SDNN, standard deviation of
normal-to-normal beats.
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each group (P=.31) but that depressed individuals have
significantly lower SDNNs and RSAs than controls
(P .001). Heart rate was significantly lower and SDNN
and RSA were significantly higher in the supine resting
condition compared with the sitting andmore active test
conditions (P .001). Mixedmodel analysis reported an
interaction effect for MDD status and assessment condi-
tion in heart rate (P .001), SDNN (P=.07), and RSA
(P=.007). This was due to a slightly larger group differ-
ence during supine resting than during interview 1, the
cognitive computer task, or interview 2. Because the dif-
ferences in heart rate, SDNN, and RSA between MDD
groups in the latter 3 test conditions were very similar,
they were collapsed into a single test condition.
Table 2 presents unadjusted and adjusted results of
the mean heart rate, SDNN, and RSA for the control, re-
mitted MDD, and current MDD groups for the resting
and test conditions. In neither condition did the remit-
ted MDD group (P=.73, fully adjusted for resting con-
dition; P=.14, for test condition) or current MDD group
(P=.87, fully adjusted for resting condition; P=.13, for
test condition) differ significantly from the controls for
heart rate. However, the currentMDD and remittedMDD
groups differed significantly from the control group in
mean SDNN and RSA in both conditions (P .01, un-
adjusted). In adjusted analyses, the currentMDDbut not
the remitted MDD group continued to have signifi-
cantly lower SDNNs comparedwith controls. Effect sizes
for lower SDNNs among the current MDD group were
small to modest (in resting condition, d=0.176; in the
test condition, d=0.125). Depressed participants also
showed significantly lower RSAs than controls; for this
parameter, lower values were found in the remitted as
well as the current MDD groups. The effect sizes were
0.215 and 0.232 for current MDD and remitted MDD,
respectively, vs controls at resting and 0.226 and 0.269
during the test condition. There were no significant dif-
ferences in RSA between the remitted and current MDD
groups themselves (P=.39, for resting conditions; P=.70,
for test conditions).
To examine whether comorbid anxiety disorders and
psychoactivemedication contributed to the lower SDNN
and RSA found in participants with MDD, these vari-
ables were examined in subsequent adjusted analyses of
covariance. Inclusion of indicators for comorbid panic
disorder, social phobia, and generalized anxiety disor-
der did not change the differences in SDNN or RSA be-
tween MDD groups. After correction for psychoactive
Table 2. Heart Rate, SDNN, and RSA by MDD Diagnosis in Resting and Test Conditions
Characteristic
Mean (SE)
Controls vs
Remitted MDD
Controls vs
Current MDD
Controls
(n=524)
Participants With
Remitted MDD
(n=774)
Participants With
Current MDD
(n=1075) t Scorea P Value t Scorea P Value
Heart Rate, Beats/min
Resting condition
Unadjusted 67.5 (0.4) 67.7 (0.4) 68.5 (0.3) 0.5 .63 2.0 .04
Adjustedb 67.7 (0.4) 67.8 (0.4) 68.4 (0.3) 0.3 .89 1.4 .17
Adjustedc 68.1 (0.4) 67.9 (0.3) 68.2 (0.3) −0.2 .73 0.2 .87
Test condition
Unadjusted 73.6 (0.4) 72.1 (0.4) 72.7 (0.3) −1.6 .12 −0.6 .57
Adjustedb 73.1 (0.4) 72.3 (0.4) 72.6 (0.3) −1.4 .16 −0.9 .38
Adjustedc 73.2 (0.4) 72.4 (0.4) 72.4 (0.3) −1.5 .14 −1.6 .13
SDNN, ms
Resting condition
Unadjusted 81.4 (1.5) 75.9 (1.2) 73.5 (1.1) −2.8 .005 −4.2 .001
Adjustedb 79.9 (1.4) 77.9 (1.2) 72.8 (1.0) −1.1 .26 −4.1 .001
Adjustedc 79.1 (1.4) 77.7 (1.2) 73.4 (1.0) −0.8 .43 −3.2 .001
Test condition
Unadjusted 68.4 (1.1) 64.8 (0.9) 64.1 (0.8) −2.5 .01 −3.1 .002
Adjustedb 67.5 (1.1) 65.9 (0.9) 63.7 (0.7) −1.2 .25 −2.9 .003
Adjustedc 67.1 (1.1) 65.7 (0.9) 64.0 (0.8) −1.0 .31 −2.3 .02
RSA, ms
Resting condition
Unadjusted 52.1 (1.4) 43.9 (1.1) 45.1 (0.9) −4.7 .001 −4.2 .001
Adjustedb 51.6 (1.1) 45.6 (0.9) 44.2 (0.8) −4.1 .001 −5.3 .001
Adjustedc 51.4 (1.2) 45.5 (0.9) 44.3 (0.8) −4.0 .001 −5.0 .001
Test condition
Unadjusted 47.7 (1.1) 41.6 (0.9) 43.4 (0.8) −4.2 .001 −3.2 .002
Adjustedb 47.5 (0.9) 43.1 (0.8) 42.4 (0.7) −3.6 .001 −4.4 .001
Adjustedc 47.6 (1.0) 42.9 (0.8) 42.5 (0.7) −3.8 .001 −4.3 .001
Abbreviations: MDD, major depressive disorder; RSA, respiratory sinus arrhythmia; SDNN, standard deviation of normal-to-normal beats.
aBased on t statistics for contrast comparison with 1 df.
bAdjusted for respiration rate, age, sex, and education.
cAdjusted for respiration rate, age, sex, education, body mass index, physical activity, smoking, alcohol use, heart disease, chronic diseases, and heart
medication.
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 65 (NO. 12), DEC 2008 WWW.ARCHGENPSYCHIATRY.COM
1362
©2008 American Medical Association. All rights reserved.
 at Vrije Universiteit, on December 1, 2010 www.archgenpsychiatry.comDownloaded from 
medication, however, the differences between MDD
groups and controls were strongly attenuated; differ-
ences in SDNN between the current MDD group and the
controls lost significance (P=.37, resting condition;P=.72,
test condition), though they remained significant for RSA
in the resting condition (P=.05) and borderline signifi-
cant in the test condition (P=.10).
Because the differences between MDD groups disap-
peared for SDNN and were strongly attenuated for RSA
after considering psychoactivemedication, the individu-
als with MDD (either current or remitted) were further
divided on the basis of medication use: those taking and
not taking certain medications. Since individuals with
MDD not using psychoactive medications had a lower
mean severity IDS-SR score than those taking medica-
tion, nonmedicatedMDD participants were divided into
a mildly to moderately depressed group (IDS-SR score
25) and a severely depressed group (IDS-SR score25).
The latter nonmedicated grouphad a similarmean IDS-SR
score as the depressed individuals using medication
(Table3). Eventually 6 groups of individuals withMDD
were distinguished: 585mildly to moderately depressed
individuals not taking medication (IDS-SR score 25),
436 severely depressed individuals not taking medica-
tion (IDS-SR score 25), 67 depressed individuals tak-
ingTCAs, 435depressed individuals taking SSRIs (noTCA
users), 137 depressed individuals taking other antide-
pressants (no TCA or SSRI users), 63 depressed indi-
viduals taking benzodiazepines (no antidepressants), and
104depressed individuals taking other psychoactivemedi-
cations (no antidepressants or benzodiazepines). Analy-
ses of covariancewere performed to compare these groups
for the resting and test conditions.
Table 3 and Figure2 present the fully adjusted analy-
ses of covariance results for SDNN and RSA across the
different groups. For SDNN, the difference across MDD
groups appears to be entirely due to psychoactive medi-
cation use, as depressed participants not taking medica-
tion, with either mild to moderate or severe symptoms,
did not have significantly lower SDNNs than controls.
For RSA, the depressed groups not using psychoactive
medications still had significantly lower restingRSAs com-
pared with the control group; this was independent of
severity of symptoms (controls vsMDDparticipants with
IDS-SR scores 25, P=.05; controls vs MDD partici-
pants with IDS-SR scores25, P=.05). The effect sizes,
however, were reduced by half. In the test condition, sig-
nificance decreased to borderline levels only (controls
Table 3. SDNN and RSA by Medication Groupa
Study Group
No. of
Participants
IDS-SR
Score,
Mean
Resting Condition Test Condition
Measure,
Mean (SE),
ms
t
Scoreb
P
Value Cohen d
Measure,
Mean (SE),
ms
t
Scoreb
P
Value Cohen d
SDNN
Controlsc 515 5.6 79.5 (1.4) 67.4 (1.1)
Participants with MDD not taking
medication
With mild symptomsd 585 15.9 79.8 (1.3) 0.2 .86 0.011 67.4 (1.0) −0.03 .97 0.002
With severe symptomse 433 35.9 77.8 (1.5) −0.8 .44 0.051 67.9 (1.2) 0.3 .79 0.018
Participants with MDD taking
medication
TCA 67 34.3 56.1 (3.9) −5.6 .001 0.727 46.6 (3.0) −6.5 .001 0.849
SSRI 435 34.4 71.7 (1.5) −3.7 .001 0.243 62.3 (1.2) −3.1 .002 0.207
Other AD 134 34.8 62.1 ( 2.7) −5.6 .001 0.542 57.8 (2.1) −4.1 .001 0.395
Benzodiazepine 63 37.0 72.2 (4.1) −1.7 .10 0.227 64.0 (3.1) −1.0 .30 0.139
Other psychoactive medication 104 31.3 81.1 (3.2) 0.5 .64 0.051 65.9 (2.4) −0.6 .57 0.062
RSA
Controlsc 515 5.6 51.8 (1.2) 48.0 (1.0)
Participants with MDD not taking
medication
With mild symptomsd 585 15.9 48.8 (1.1) −1.9 .05 0.116 45.7 (0.9) −1.7 .08 0.107
With severe symptomse 433 35.9 48.5 (1.2) −1.9 .05 0.127 45.4 (1.0) −1.3 .07 0.120
Participants with MDD taking
medication
TCA 67 34.3 31.5 (3.1) −6.0 .001 0.787 29.4 (2.6) −6.0 .001 0.862
SSRI 435 34.4 39.0 (1.2) −7.5 .001 0.493 39.1 (1.0) −6.2 .001 0.413
Other AD 134 34.8 34.3 (2.2) −7.0 .001 0.680 35.6 (1.8) −6.6 .001 0.575
Benzodiazepine 63 37.0 46.5 (3.2) −1.5 .12 0.207 44.2 (2.7) −1.8 .19 0.175
Other psychoactive medication 104 31.3 49.4 (2.6) −0.9 .39 0.094 44.0 (2.1) −1.8 .09 0.183
Abbreviations: AD, antidepressant; IDS-SR, Inventory of Depressive Symptoms Symptomatology, Self-Report; MDD, major depressive disorder; RSA, respiratory
sinus arrhythmia; SDNN, standard deviation of normal-to-normal beats; SE, standard error; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
aAdjusted for respiration rate, age, sex, education, body mass index, physical activity, smoking, alcohol use, heart disease, chronic diseases, and heart medication.
bBased on t statistics for contrast comparison with 1 df.
cControls are the reference group. All t scores, P values, and effect sizes are for comparison of the group with controls.
dBased on an IDS-SR score of less than 25.
eBased on an IDS-SR score of 25 or higher.
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vsMDDparticipantswith IDS-SR scores25,P=.08; con-
trols vs MDD participants with IDS-SR scores 25,
P=.07).
Depressed participants taking benzodiazepines did not
differ fromcontrolsbySDNNorRSA(Figure2andTable3).
In contrast, SDNN and RSA differed significantly between
controls and depressed individuals taking TCAs, SSRIs, or
other antidepressants in both conditions (P.002, all).De-
pressedparticipants usingoneof thesemedicationshad sig-
nificantly lower SDNNs andRSAs than controls,with effect
sizes ranging from 0.207 to 0.862.
Table 4 presents the results of partial correlations
between the derived daily dose of each antidepressant
group and their correlations with SDNN and RSA. Cor-
relations were only calculated for medication types that
were used by at least 20 participants. All antidepres-
sants had a negative correlation with the heart rate vari-
ability measures, indicating that SDNN and RSA were
lowerwhen dosagewas higher.Withinmedication classes
(TCAs, SSRIs, and other antidepressants), correlations
were similar and consistent acrossmedication types. Dif-
ferences between significant and nonsignificant correla-
tions are therefore mainly due to differences in sample
size and very likely not due to differential effects for spe-
cific medications within medication type. Repeating all
of these analyses using RMSSD yielded a very similar pat-
tern of results (data not shown).
COMMENT
This large-scale cohort study showed rather clearly that,
when compared with healthy controls, depressed indi-
viduals have significantly lower total heart rate variabil-
ity and significantly lower heart rate variability in the res-
piratory frequency range, which is considered to reflect
lower cardiac vagal control.23,50 This is in keeping with a
previous meta-analysis of much smaller studies.22 Co-
morbid anxiety or lifestyle factors, including physical ac-
tivity, did not explain the lower SDNNs or RSAs in de-
pressed individuals. Instead, the association appeared to
be driven mainly by the effects of antidepressants. De-
pressed participants taking antidepressants showed sig-
nificantly lower SDNNs (d=0.207 to d=0.849) and lower
RSAs (d=0.413 to d=0.862), whereas differences be-
tween controls and depressed individuals not taking an-
tidepressants were much smaller for RSA (approxi-
mately, d=0.118) and even nonsignificant for SDNN.
Wefoundnotonlyconsistently lowerSDNNsandRSAs
indepressedpatientsusingTCAs, SSRIs, andother antide-
Mild 
Symptoms
Controls
Participants With MDD
Not Taking Medication
Participants With MDD
by Medication
Severe 
Symptoms
Other Psychoactive
Medication
TCA SSRI Other 
Antidepressant
Benzodiazepine
55
45
50
35
40
30
25
RS
A,
 m
s
85
75
Resting Test
80
55
65
70
50
60
45
SD
NN
, m
s
Figure 2. Mean adjusted standard deviation of normal-to-normal beats (SDNN) and respiratory sinus arrhythmia (RSA) in major depressive disorder (MDD)
medication group for resting and test conditions. Values were adjusted for respiration rate, age, sex, education, body mass index, physical activity, smoking,
alcohol use, heart disease, chronic diseases, and heart medication. Mild MDD was defined as a score of less than 25 on the 30-item Inventory of Depressive
Symptomatology, Self-Report; severe MDD was defined as a score of 25 or greater. SSRI indicates selective serotonin reuptake inhibitor; TCA, tricyclic
antidepressant.
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pressants, but also an indication for a dose-response effect
for all 3 medication classes, as a higher derived daily dose
was significantly associatedwith lower heart rate variabil-
ity. The lower SDNNs andRSAs in TCA and other antide-
pressantuserscomparedwithcontrolswereconsistentwith
results from other studies.27-33 Rechlin29 found a decrease
in heart rate variability in amitriptyline users (n=8) com-
paredwithnonmedicateddepressedpatients(n=32).Tulen
et al30 also reported such an effect for imipramine (n=10)
andmirtazapine (n=10). In addition,Volkers et al33 found
a reduction in parasympathetic activity after use of imip-
ramine (n=17)and fluvoxamine (n=24).Rooseet al32 also
found a reduction inheart rate variability (P .01) and an
11%increaseinheartrate(P.001)afternortriptylinetreat-
ment (n=40). Our results also agree with those obtained
byGlassman et al31 in the Sertraline Antidepressant Heart
AttackRandomizedTrial. In258patientswith acute coro-
nary syndromewhowere randomized to either placeboor
sertralineafteracoronaryevent,powerinthelow-frequency
rangesignificantlydecreasedinthesertralinegroupandhigh-
frequencypowerdecreasedby9.2%duringtreatment,though
this difference failed to be significant.
Although antidepressant medication explained a large
part of the observed differences in RSA between the de-
pressed and nondepressed groups, we also found some-
what lower RSAs in nonmedicated depressed individuals
than in controls. These effects of depression, which were
not significantly present for SDNN, do not seem to be
caused by depressed mood at the time of baseline assess-
ment, independent of a history of depression. Respiratory
sinus arrhythmia was not lower in the current MDD
group than in the remitted MDD group. Instead, both
groups had significantly lower cardiac vagal control com-
pared with controls. Hence, our results are compatible
with theoretical models, like the polyvagal theory, that
have explicitly linked the parasympathetic nervous sys-
tem to the etiology of depression, in part because impair-
ments of low vagal tone are associatedwith reduced social
engagement and a less flexible behavioral response to en-
vironmental changes.19-22 In the context of this theory, it
has been suggested that depressed individuals may show
less context-appropriate vagal withdrawal.22,57 A limita-
tion of our study is that it cannot directly test this theory,
as this requires task manipulations that induce a substan-
tial amount of stress, which were not included in NESDA.
Our contrast between resting and test conditions does not
qualify as stress manipulation and was also confounded
with a postural change (supine vs sitting). Consequently,
we could not assess the effect of depression on stress-
induced vagal reactivity.
The association between antidepressant use and low
heart rate variability was robust in our study, but we ac-
knowledge that the cross-sectional setup is a further limi-
tation of our study. Without experimental longitudinal
data, we do not know whether antidepressants caused
the low SDNNs and RSAs or whether such effects would
be reversed when individuals stop taking their medica-
tions. We also cannot completely exclude the possibil-
ity that depressed individuals taking antidepressants dif-
fered from thedepressed individuals not takingmedication
by 1 or more clinical aspects. However, the most likely
aspect, difference in depression symptom severity, did
not seem to explain the findings. These study limita-
tions are balanced by strong points. We used a large
sample of patients, both medicated and nonmedicated,
who were ascertained in multiple ways to obtain a rep-
resentative population sample of patients. In addition,
the availability of prolonged ambulatory recordings in the
nearly complete sample provided us with stable and re-
liable indicators of heart rate variability.
Table 4. Correlation Between Derived Daily Dose (DDD) and SDNN or RSA Among Depressed Individuals
Using Psychoactive Medication
Psychoactive
Medication
No. of
Participants
DDD,a
Mean (SD)
Resting Condition Test Condition
DDD and SDNNb DDD and RSAb DDD and SDNNb DDD and RSAb
r P Value r P Value r P Value r P Value
Tricyclic antidepressants
All combined 67 0.85 (0.59) −0.295 .02 −.281 .03 −0.394 .002 −0.335 .008
Clomipramine 28 0.93 (0.52) −0.316 .12 −.304 .14 −0.504 .01 −0.290 .16
Amitriptyline 30 0.67 (0.56) −0.276 .16 −.271 .17 −0.317 .11 −0.252 .22
SSRIs
All combined 435 1.36 (0.65) −0.205 .001 −0.161 .001 −0.204 .001 −0.168 .001
Fluoxetine 59 1.31 (0.52) −0.219 .12 −0.080 .57 −0.148 .29 −0.121 .39
Citalopram 97 1.43 (0.65) −0.189 .07 −0.186 .08 −0.167 .11 −0.148 .16
Paroxetine 197 1.27 (0.56) −0.235 .001 −0.169 .02 −0.224 .002 −0.166 .02
Sertraline 43 1.72 (0.93) −0.142 .38 −0.112 .49 −0.342 .03 −0.266 .10
Fluvoxamine 46 1.29 (0.61) −0.159 .33 −0.274 .09 −0.114 .49 −0.215 .18
Other antidepressants
All combined 137 1.26 (0.60) −0.151 .09 −0.278 .001 −0.201 .02 −0.295 .001
Mirtazapine 36 1.03 (0.44) −0.147 .42 −0.204 .26 −0.348 .05 −0.248 .17
Venlafaxine 100 1.31 (0.60) −0.168 .10 −0.069 .51 −0.188 .06 −0.110 .28
Abbreviations: RSA, respiratory sinus arrhythmia; SDNN, standard deviation of normal-to-normal beats; SSRI, selective serotonin reuptake inhibitor.
aDerived daily dose is expressed as the daily dose used by participants divided by the defined daily dose assigned by the World Health Organization. The
defined daily dose is the assumed average maintenance dose per day for a drug used for its main indication in adults. Analyses for specific psychoactive
medications were performed when at least 20 participants were using that particular medication.
bAdjusted for sex and age.
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Our findings demonstrate that depressed persons have
lower total heart rate variability with lower cardiac vagal
control, but these effects are mostly derived from de-
pressed persons using antidepressants. Because it has been
widely established that lowered heart rate variability is a
risk factor for cardiovascular morbidity andmortality,12-18
our findings could be of importance to clinical practice. It
is an open question whether the lower SDNNs and RSAs
outweigh the beneficial effects of antidepressant medica-
tion on future heart disease. In view of the large number
of patients comorbid for depression and heart disease, we
argue that this question needs to be addressed.
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